Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Climb Bio (CLYM) Non-Current Assets (2020 - 2026)

Climb Bio filings provide 7 years of Non-Current Assets readings, the most recent being $39.0 million for Q1 2026.

  • Quarterly Non-Current Assets fell 61.21% to $39.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $297.2 million through Mar 2026, up 58.61% year-over-year, with the annual reading at $61.9 million for FY2025, 0.67% down from the prior year.
  • Non-Current Assets hit $39.0 million in Q1 2026 for Climb Bio, down from $61.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $105.0 million in Q2 2025 and bottomed at $21000.0 in Q2 2024.
  • Average Non-Current Assets over 5 years is $32.0 million, with a median of $17.0 million recorded in 2022.
  • The largest annual shift saw Non-Current Assets plummeted 98.97% in 2024 before it soared 499909.52% in 2025.
  • Climb Bio's Non-Current Assets stood at $599000.0 in 2022, then crashed by 64.27% to $214000.0 in 2023, then soared by 29019.16% to $62.3 million in 2024, then decreased by 0.67% to $61.9 million in 2025, then crashed by 37.04% to $39.0 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Non-Current Assets are $39.0 million (Q1 2026), $61.9 million (Q4 2025), and $91.3 million (Q3 2025).